NEW YORK and TEL AVIV, Israel, April 4, 2011 /PRNewswire/ -- Signal Genetics, the parent company of Myeloma Health LLC, and Pronto Diagnostics Ltd, both of which are privately held predictive genetic testing companies focused on oncology, announced that they have entered into a Distribution Agreement whereby Pronto will be the exclusive representative and distributor for Signal's Myeloma Prognostic Risk Signature (MyPRS) test in Israel.
According to Joe Hernandez, CEO of Signal Genetics, "The Agreement with Pronto Diagnostics represents our initial entry into the international market with MyPRS and strong interest among both laboratories and physicians outside the United States in providing broader access to this novel technology." Signal's MyPRS test is performed at the company's CLIA lab located in Little Rock, Arkansas and has been adopted by several highly reputable academic cancer centers throughout the U.S.
Dr. Nir Navot, Chairman and CTO of Pronto Diagnostics affirmed: "Our agreement with Signal Genetics allows us to provide a valuable prognostic tool to Israeli hematologists who treat Myeloma patients, in line with our commitment to increasing personalization of treatment for cancer patients".
About Signal Genetics
Signal Genetics, the parent company of Myeloma Health, is a privately held predictive genetic testing company focused on helping cancer patients. The goal of Signal Genetics is to provide cancer patients and their physicians with novel and innovative insights into their disease, including predictive outcome of disease stage, odds of relapse, and the optimal treatment regimen based on their specific genetic expression profile. Additional information is available at www.signalgenetics.com.
About Pronto Diagnostics
Pronto Diagnostics is a privately held company based in Tel Aviv that provides services for molecular diagnosis of disease with a focus on oncology, including the development and distribution of genetic testing kits. Pronto has similar distribution relationships with several molecular diagnostic companies including Ipsogen, Pathwork Diagnostics, and Epigenomics. Additional information is available at www.prontodiagnostics.com.
|SOURCE Signal Genetics|
Copyright©2010 PR Newswire.
All rights reserved